for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DexCom, Inc.

DXCM.O

Latest Trade

440.50USD

Change

0.00(0.00%)

Volume

1,068,725

Today's Range

428.50

 - 

445.52

52 Week Range

138.28

 - 

445.52

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
440.50
Open
435.80
Volume
1,068,725
3M AVG Volume
37.75
Today's High
445.52
Today's Low
428.50
52 Week High
445.52
52 Week Low
138.28
Shares Out (MIL)
94.30
Market Cap (MIL)
41,029.97
Forward P/E
189.59
Dividend (Yield %)
--

Next Event

Q2 2020 DexCom Inc Earnings Release

Latest Developments

More

Dexcom Prices Offering Of Upsized $1.05 Billion Of 0.25% Convertible Senior Notes

Dexcom Reports Proposed Offering Of $850.0 Million Of Convertible Senior Notes

DexCom Reports Q1 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DexCom, Inc.

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Industry

Medical Equipment & Supplies

Contact Info

6340 Sequence Dr

SAN DIEGO, CA

92121-4356

United States

+1.858.2000200

http://www.dexcom.com

Executive Leadership

Kevin R. Sayer

Chairman of the Board, President, Chief Executive Officer

Quentin S. Blackford

Chief Financial Officer, Chief Operating Officer

Jake Steven Leach

Executive Vice President, Chief Technology Officer

Donald M. Abbey

Executive Vice President - Quality and Regulatory Affairs

Andrew K. Balo

Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development

Key Stats

1.65 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.7K

2018

1.0K

2019

1.5K

2020(E)

1.8K
EPS (USD)

2017

-0.580

2018

0.300

2019

1.840

2020(E)

2.295
Price To Earnings (TTM)
273.23
Price To Sales (TTM)
25.63
Price To Book (MRQ)
42.98
Price To Cash Flow (TTM)
205.46
Total Debt To Equity (MRQ)
116.28
LT Debt To Equity (MRQ)
116.28
Return on Investment (TTM)
7.70
Return on Equity (TTM)
6.69

Latest News

Latest News

BRIEF-Dexcom Prices Offering Of Upsized $1.05 Billion Of 0.25% Convertible Senior Notes

* DEXCOM PRICES OFFERING OF UPSIZED $1.05 BILLION OF 0.25% CONVERTIBLE SENIOR NOTES

BRIEF-Dexcom Reports Proposed Offering Of $850.0 Million Of Convertible Senior Notes

* DEXCOM ANNOUNCES PROPOSED OFFERING OF $850.0 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Health Canada Temporarily Authorizes Dexcom G6 Cgm For Use In Hospitals

* HEALTH CANADA TEMPORARILY AUTHORIZES DEXCOM G6 CGM FOR USE IN HOSPITALS TO MONITOR CRITICALLY ILL PATIENTS DURING COVID-19 PANDEMIC Source text for Eikon: Further company coverage:

BRIEF-DexCom Reports Q1 2020 Financial Results

* Q1 REVENUE $405.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $358 MILLION

BRIEF-Dexcom And Insulet Announce Commercial Agreement

* DEXCOM AND INSULET ANNOUNCE COMMERCIAL AGREEMENT TO INTEGRATE THE DEXCOM G6 AND FUTURE G7 CGM INTO INSULET’S OMNIPOD HORIZON AUTOMATED INSULIN DELIVERY SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Dexcom Reports Q4 Earnings Per Share $1.00

* DEXCOM REPORTS FOURTH QUARTER AND FISCAL YEAR 2019 FINANCIAL RESULTS

CORRECTED-Dexcom says diabetes monitoring software malfunctioning since Saturday

Dexcom Inc, which makes continuous glucose monitoring systems that can be used by adults to track sugar levels in children with diabetes, said on its website Sunday that some users of a monitoring software called Dexcom Follow were not receiving data or alerts as intended.

BRIEF-DexCom Reports Q1 GAAP Loss Per Share Of $0.28

* Q1 REVENUE $184.4 MILLION VERSUS I/B/E/S VIEW $172.3 MILLION

BRIEF-FDA Authorizes Marketing Of New Dexcom G6 CGM Eliminating Need For Fingerstick Blood Testing

* FDA AUTHORIZES MARKETING OF THE NEW DEXCOM G6® CGM ELIMINATING NEED FOR FINGERSTICK BLOOD TESTING FOR PEOPLE WITH DIABETES

BRIEF-U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System

* U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM

BRIEF-Dexcom Inc Q4 GAAP Loss Per Share $0.11

* DEXCOM REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

BRIEF-DexCom Says Preliminary Q4 Revenue Was $218 Mln

* DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK

BRIEF-Dexcom announces development agreement with Lilly

* Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem

BRIEF-Dexcom Inc reports Q3 GAAP loss per share $0.02

* Dexcom, inc. Reports record third quarter 2017 financial results

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers

BRIEF-‍Janus Henderson reports 10.2 pct passive stake in Dexcom

* Janus Henderson Group PLC reports a 10.2 percent passive stake in Dexcom Inc as of sept 30 - SEC filing Source text: (http://bit.ly/2ybb4kH) Further company coverage:

BRIEF-Fitbit and Dexcom to develop Continuous Glucose Monitoring Experience for people living with diabetes

* Fitbit and DexCom to develop Continuous Glucose Monitoring (CGM) experience for people living with diabetes

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

BRIEF-DexCom ‍publishes new study on people with type 2 diabetes

* DexCom- published new study showing type 2 diabetes people on a multiple daily injection insulin therapy benefit from use of continuous glucose monitoring Source text for Eikon: Further company coverage:

BRIEF-Dexcom Q2 revenue $170.6 mln; names new CFO

* Q2 revenue $170.6 million versus I/B/E/S view $166.3 million

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up